Topical Estrogen Accelerates Hair Regrowth in Mice After Chemotherapy-Induced Alopecia by Favoring the Dystrophic Catagen Response Pathway to Damage

This study observed that in vitro treatment of male frontotemporal scalp hair follicles with 17-β-estradiol stimulated hair shaft generation and hair matrix keratinocyte proliferation, suggesting potential anagen-prolonging effects.

Estrogen receptor α controls hair growth cycles and skin thickness in male mice.

This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.

This study found that the effectiveness of 17-beta-estradiol in inhibiting hair growth depends on its application method, and noted significant sex differences in response to 17-alpha-estradiol in male and female mice.

This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.

In this study, different types of catagen in the C57BL/6 mouse model exhibited varying effects on hair follicle melanocytes and melanin distribution, with spontaneous and dexamethasone-induced catagen showing pigment incontinence, while cyclophosphamide-induced catagen retained dendritic melanocytes but increased ectopic melanin.

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.

This study found that 17-beta-estradiol inhibits hair growth in mice by blocking hair follicles in the telogen phase, whereas an estrogen receptor antagonist promotes hair growth by initiating anagen.

This study introduces a mouse model of cyclophosphamide-induced alopecia, which effectively replicates human chemotherapy-induced hair loss and can be pharmacologically manipulated to study hair regrowth patterns.

This article discusses the cutaneous side effects of various chemotherapeutic agents but reports no new clinical results; the authors emphasize the importance of dermatologists recognizing drug-induced skin reactions to better patient care.

This article reviews studies on thyroid influence on hair growth, noting varied results, including accelerated growth in some normal and underfed rats after thyroid administration, but reports no clinical results.